Hua Medicine Successfully Completes Its Registration Phase III Trials; Announces 52-Week Results for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial
- Written by ACN Newswire
SHANGHAI, CHINA, Dec 18, 2020 - (ACN Newswire) - Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced:
|
- Successfully completes two Phase III 53-week registration trials in over 1,200+ Chinese patients in the midst of...